Dual inhibition of EZH2 and ATM displays synergistic cytotoxicity in BRCA1-deficient breast

被引：0
|
作者：
Puppe, J. [1 ]
Brambillasca, C. [2 ]
Ratz, L. [3 ]
Bartke, L. [3 ]
van de Ven, M. [2 ]
Bouwman, P. [2 ]
van Tellingen, O. [2 ]
Isensee, J. [4 ]
Hucho, T. [4 ]
van Lohuizen, M. [2 ]
Malter, W. [3 ]
Schmutzler, R. [5 ]
Mallmann, P. [3 ]
Jonkers, J. [2 ]
Reinhardt, C. [6 ]
机构：
[1] Uniklin Koln, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Cologne, Germany
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Uniklin Koln, Klin & Poliklin Frauenheilkunde, Cologne, Germany
[4] Uniklin Koln, Cologne, Germany
[5] Uniklin Koln, Zentrum Familiarer Brust & Eierstockkrebs, Cologne, Germany
[6] Uniklin Koln, Innere Med Klin 1, Cologne, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2020年 / 80卷 / 10期
关键词：
D O I：
10.1055/s-0040-1717869
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P037
引用
收藏
页码：E104 / E104
页数：1
相关论文
共 50 条
  • [21] Chemopreventive Effects of ROS Targeting in a Murine Model of BRCA1-Deficient Breast Cancer
    Li, Mo
    Chen, Qian
    Yu, Xiaochun
    CANCER RESEARCH, 2017, 77 (02) : 448 - 458
  • [22] BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
    Lei, Guang
    Mao, Chao
    Horbath, Amber D.
    Yan, Yuelong
    Cai, Shirong
    Yao, Jun
    Jiang, Yan
    Sun, Mingchuang
    Liu, Xiaoguang
    Cheng, Jun
    Xu, Zhihao
    Lee, Hyemin
    Li, Qidong
    Lu, Zhengze
    Zhuang, Li
    Chen, Mei-Kuang
    Alapati, Anagha
    Yap, Timothy A.
    Hung, Mien-Chie
    You, Mingjian James
    Piwnica-Worms, Helen
    Gan, Boyi
    CANCER DISCOVERY, 2024, 14 (08) : 1476 - 1495
  • [23] Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
    Belz, Jodi E.
    Kumar, Rajiv
    Baldwin, Paige
    Ojo, Noelle Castilla
    Leal, Ana S.
    Royce, Darlene B.
    Zhang, Di
    van de Ven, Anne L.
    Liby, Karen T.
    Sridhar, Srinivas
    THERANOSTICS, 2017, 7 (17): : 4340 - 4349
  • [24] Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer
    Ewa Malgorzata Michalak
    Jos Jonkers
    Journal of Mammary Gland Biology and Neoplasia, 2011, 16 : 41 - 50
  • [25] EZH2 takes the stage when BRCA1 loses
    Wang, Lan
    Huang, Haojie
    CELL CYCLE, 2013, 12 (23) : 3575 - 3576
  • [26] Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors
    Lanzi, Cinzia
    Arrighetti, Noemi
    Pasquali, Sandro
    Cassinelli, Giuliana
    BIOCHEMICAL PHARMACOLOGY, 2023, 215
  • [27] Novel epigenetic approach to relapsed mantle cell lymphoma based on dual inhibition of EZH1/EZH2
    Fujita, Shuhei
    Kagiyama, Yuki
    Honma, Daisuke
    Adachi, Nobuaki
    Araki, Kazushi
    Kitabayashi, Issay
    CANCER RESEARCH, 2017, 77
  • [28] Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
    Yeo, Syn Kok
    Paul, Ritama
    Haas, Michael
    Wang, Chenran
    Guan, Jun-Lin
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 72 - 73
  • [29] PARP inhibition modulates the tumor immune microenvironment in Brca1-deficient ovarian tumor.
    Ding, Liya
    Wang, Qiwei
    Kearns, Michael
    Jiang, Tao
    Konstantinopoulos, Panagiotis
    Matulonis, Ursula
    Zhao, Jean
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 23 - 23
  • [30] EZH2 Regulates Growth of Estrogen Receptor Negative Breast Carcinomas by Regulating BRCA1 Localization
    Gonzalez, M. E.
    Li, X.
    Toy, K.
    DuPrie, M.
    Kleer, C. G.
    MODERN PATHOLOGY, 2010, 23 : 386A - 386A
12345